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The purpose of this study was to investigate the prognostic value of the primary in situ cellular immune response in cervical squamous
cell carcinoma. A study of 102 women treated for stage IB and IIA disease, between 1990 and 2000, was performed. Paraffin-
embedded cervical tissue processed at the time of diagnosis was immunostained for CD3þ (T cells), CD4þ (T helper/regulatory
T cells) and CD8þ (cytotoxic T cells) cells. Immune cell profile densities were estimated using stereology. Both intra- and
peritumoural cell densities were estimated. Using Cox’s proportional hazards regression modelling we found an increase in cell
density to decrease the risk of relapse for all three cell types. The density of peritumoural CD3þ cells seems to have the strongest
potential for predicting relapse. An increase in CD3þ cell density from 795 to 2043 cells per mm
2 (25–75 percentile) reduced the
hazard ratio to 0.27.
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Cervical cancer is a common cancer in women worldwide (Parkin
et al, 2005). A necessary condition for development of cervical
cancer is persistent infection with human papilloma virus (HPV)
of certain subtypes (Bosch and Munoz, 2002), particularly types 16
and 18. New and promising vaccines to prevent HPV infection
have been developed (Koutsky and Harper, 2006); however, the
vaccines do not protect against all HPV subtypes and they
primarily elicit their effect in women not already infected. Cervical
cancer will, for decades to come, still remain a serious health
problem, and to improve survival new parameters for prognosis
and new adjuvant treatments are needed.
There are several well-known prognostic factors, including
clinical stage, spread of the cancer to lymph nodes, tumour
size and depth of invasion (Kristensen et al, 1999; Singh and
Arif, 2004). Because cervical cancer is preconditioned by a
virus infection, the immune response towards the cancer is
potentially important for overcoming the disease by clearing or
controlling the viral infection. Previous studies have shown
infiltration of immune cells also to be associated with improved
clinical outcome in cancer patients (Bethwaite et al, 1996; Chao
et al, 1999).
Also in other cancers such as ovarian cancer (Zhang et al, 2003;
Sato et al, 2005) and endometrial cancer (Kondratiev et al, 2004),
has the immune response towards the cancer cells been associated
with prognosis.
In a previous study we found a striking difference in the
numbers of both intra- and peritumoural CD3þ, CD4þ and
CD8þ cells in biopsies between women who were cured by
primary treatment for stage IB cervical squamous cell carcinomas
and women who experienced a relapse. To further explore the
value of these results we made this cohort study including 102
patients treated for stage IB and IIA disease at a single institution.
The in situ cellular immune response was investigated with respect
to densities of T cells (CD3þ), T helper cells/regulatory T cells




The study included 102 patients treated for cervical squamous cell
carcinoma, International Federation of Obstetrics and Gynecology
(FIGO) stage IB and IIA, at Aalborg Hospital from 1990 to 2000
(Table 1). Patients were clinically staged according to the FIGO
criteria (Benedet et al, 2000). If operable, patients underwent
hysterectomy with pelvic lymph node dissection and in cases of
increased risk of relapse (assessed from depth of invasion, vascular
invasion, spread to lymph nodes, invasion of the parametrium and
cancer close to resection margins) radiotherapy was added.
Inoperable patients were treated by radiotherapy (both external
radiotherapy and brachytherapy). Patients were not included in
the study if they were more than 70 years old at the time of
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sdiagnosis, or if they had previous malignant diseases. Retro-
spectively, paraffin-embedded cervical tissue processed at the time
of diagnosis was retrieved from the files at the Institute
of Pathology, Aalborg Hospital, Aarhus University Hospital,
Denmark. From each tissue biopsy, one representative block
containing cancer was included.
Immunohistochemistry
New 4mm thick sections were cut from each selected block of
formalin-fixed, paraffin-embedded tissue, using a calibrated
rotatory microtome (Leica RM 2165). Sections were mounted on
SuperFrost
RPlus slides, dried at room temperature overnight
and afterwards dried for 60min at 601C. The sections were
deparaffinised using Tissue-Clear (Sakura, Zocterwoude, The
Netherlands) for 10min. Endogenous peroxidase blocking (3ml
30% H2O2 in 200ml 99% ethanol for 15min) followed by
rehydration in a series of graded alcohol (96 and 70%) and finally
water was performed. Antigens were retrieved by pressure cooker
(heating to 1201C in Tris/EDTA retrieval buffer). After cooling in
water, slides were placed in TBS-Tween buffer for 5min. Staining
was performed using Dako autostainer at temperature 18–221C.
The primary antibodies used were mouse monoclonal anti-human
CD3 (code no. M 7254, Dako, Glostrup, Denmark) 1:40, anti-CD4
(code no. NCL-CD4-1F6, Novocastra, Newcastle, UK) 1:25 and
anti-CD8 (code no. M 7103, Dako) 1:250.
Primary antibodies were incubated for 30min and thereafter
rinsed with TBS-Tween buffer followed by amplification by a
labelled polymer conjugate (Dako EnVisionþkit K4007). After
rinsing with TBS-Tween buffer, antigen-bound antibodies were
visualised with DABþ (K4007, Dako). After another round of
rinsing with TBS-Tween buffer, the sections were counterstained
with Mayers haematoxylin for 5min. To enhance the visualisation
of the staining, the sections were incubated in 0.5% CuSO4 in TBS
buffer for 5min. At last the sections were mounted with Pertex.
Tonsil tissue was used as positive control and it was stained
together with the sections included in the research study.
Evaluation of immunostains
An Olympus light microscope (BH-50) equipped with a video
camera and connected to a PC with a computer-assisted stereology
system (CAST version 2, Olympus, Ballerup, Denmark) was used
for evaluation of the immunostained sections. The microscope had
a motorised stage controlled by the computer for precise and
random selection of fields of view within the entire area of cancer.
Immune cells were counted with respect to their location, that is,
intra- or peritumoural. An area containing stromal tissue was
denoted peritumoural, if at least one malignant cell was observed
in the field of view inside a sampling frame of an area of
31 10
3mm
2 as described in detail previously (Nedergaard et al in
press).
The chosen density of fields of view varied depending on the
density of the cells of specific subtypes to be assessed, as we aimed
to count at least 50 cells of each subtype. Cell profiles were counted
at a final screen magnification of  1024 using a 2D counting
frame and a simple, unbiased counting rule (Gundersen, 1977). For
each of the three cell immunotypes, the number of cell profiles and
their anatomical position (intra- or peritumoural) were registered.
STATISTIC ANALYSIS
Cox’s proportional hazards regression modelling was applied to
estimate the hazard rates. Both multiple and univariate models for
the different immune subtypes were performed. Crude and
adjusted hazard ratios were calculated. The models were adjusted
for age at diagnosis and FIGO stage. Based on the number of
patients it seemed unreasonable to adjust for more variables.
Kaplan–Meier survival curves were drawn. For analysis the
statistical software package R version 2.4.1 was used.
RESULTS
In Table 2 the densities of cell profiles are divided into quartiles.
The fraction of patients having a relapse is shown for each group.
Generally, for all three cell subtypes the lower the density of cell
profiles the higher the fraction of patients having relapse. The
density of peritumoural CD3þ cells seems to have the strongest
potential for predicting relapse. In the group of patients having the
lowest density of CD3þ cells, that is, first quartile, 62% had a
relapse. In the group of patients having the highest density of
CD3þ cells, that is, fourth quartile, only 12% had a relapse. In
both the second and third quartile 24% had experienced a relapse.
In a multiple regression model with age at diagnosis, FIGO stage
and the three immune cell subtypes, none of the immune cell
subtypes were independent predictors. The hazard ratios given in
Table 3 are based on univariate analyses and the adjusted hazard
ratios are adjusted for age at diagnosis and FIGO stage. The
estimates were based on changes in cell density from 25 to 75
percentiles. The crude and the adjusted model gave almost
identical results. For all cell types the hazard ratio was less than
1, that is, the risk of relapse decreased when going from a cell
Table 1 Patient characteristics
Disease free Relapse
Number of patients 71 (70%) 31 (30%)
Age at diagnosis
a 45 [26–68] 41 [22–70]
Stage IB 64 (90%) 28 (90%)
Stage IIA 7 (10%) 3 (10%)
Primary treatment surgery 62 (87%) 26 (84%)
Adjuvant radiotherapy 13 (21%) 10 (38%)
Primary treatment radiotherapy 9 (13%) 5 (16%)
aMean and range in brackets.







CD3 intratumoral I 30–293 0.50
CD3 intratumoral II 294–643 0.36
CD3 intratumoral III 644–1117 0.28
CD3 intratumoral IV 1118–3826 0.08
CD3 peritumoral I 150–794 0.62
CD3 peritumoral II 795–1300 0.24
CD3 peritumoral III 1301–2042 0.24
CD3 peritumoral IV 2043–6181 0.12
CD4 intratumoral I 0–15 0.38
CD4 intratumoral II 16–104 0.48
CD4 intratumoral III 105–212 0.20
CD4 intratumoral IV 213–1546 0.15
CD4 peritumoral I 0–105 0.52
CD4 peritumoral II 106–228 0.31
CD4 peritumoral III 229–462 0.28
CD4 peritumoral IV 463–2268 0.12
CD8 intratumoral I 9–197 0.50
CD8 intratumoral II 198–440 0.28
CD8 intratumoral III 441–851 0.24
CD8 intratumoral IV 852–5217 0.19
CD8 peritumoral I 0–447 0.54
CD8 peritumoral II 448–709 0.36
CD8 peritumoral III 710–1233 0.20
CD8 peritumoral IV 1234–4025 0.12
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sdensity at the 25 to the 75 percentile. The largest decrease in risk of
relapse was found looking at peritumoural CD3þ cells. A change
in cell density from 795 to 2043 cells per mm
2 reduced the risk of
relapse almost four times.
Figure 1 shows the cumulative proportion of relapse-free
survival for each quartile of peritumoural CD3þ cell density.
The relapse-free survival clearly differs between the first and forth
quartiles. The second and third quartiles have almost identical
relapse-free survival.
DISCUSSION
In the present study we used stereology for accurate estimation of
the 2D densities of CD3þ, CD4þ and CD8þ cell profiles in
intra- and peritumoural tissues. We investigated the association
between risk of relapse and cell densities.
In this cohort study including stage IB and IIA cervical
squamous cell carcinoma, 30% of the patients had a relapse of
disease. This is consistent with the findings in a study by Dupont
et al (2005) where 22% of patients having stage IB disease and 60%
having stage IIA disease experienced a relapse. The study included
both squamous cell carcinomas and other subtypes.
In this study there was no or very little difference between the
crude and adjusted hazard ratios for all cell types. Neither the age
at the time of diagnosis nor the FIGO stage did affect the hazard
ratios. However, there were only 10 patients having stage IIA
disease and therefore the effect of FIGO stage on hazard ratios
could not be seen. Adjustment for age was done because the ability
to raise a proper immune response changes with age (Hakim et al,
2004); however, the age at diagnosis did not differ between groups
(P¼0.1) and no effect of age was found.
We found an increase in the density of both CD3þ and CD8þ
cells to decrease the risk for relapse of disease. The decrease in
hazard ratio was highly significant for both intra- and peritu-
moural cells. An increase in density of CD4þ cells also decreased
the hazard ratio for relapse of disease, but it was only borderline
significant for intratumoural cells. The largest decrease in hazard
ratio was found for peritumoural CD3þ cells and it was 0.27 when
increasing the cell density from 795 to 2043 cells per mm
2.
The CD3 antigen is a protein complex comprising the T-cell
receptor. The antigen is expressed on all T cells and as such a pan
T-cell marker, which means that cells expressing this marker
constitute a mixture of T cells including both T helper, regulatory
and cytotoxic T cells. The presence of higher numbers of CD3þ
tumour infiltrating lymphocytes compared to lower numbers was
in a study by Bethwaite et al (1996) associated with improved
survival in stage IB cervical cancer. Chao et al (1999) consistently
found a pronounced lymphocyte infiltration to be an independent
factor of disease-free survival in stage IIB cervical squamous cell
carcinoma. Also studies of the immune response towards other
tumour types have found an association between CD3þ cells and
prognosis (Johnson et al, 2000; Zhang et al, 2003).
CD4 is a glycoprotein expressed on the surface of T helper cells
and is a co-receptor for the T-cell receptor. The antigen is also
expressed on regulatory T cells, monocytes, macrophages and
dendritic cells. Because of the differences in morphology of the
CD4þ cells, it is possible to distinguish between T cells and the
other CD4þ cells. However, in this study we cannot distinguish
between T helper and regulatory T cells. Without distinction
between T helper and regulatory T cells previous studies has been
able to find an association between prognosis and infiltration of
CD4þ T cells (Sheu et al, 1999), and low CD4þ/CD8þ ratio was
indirectly associated with worse prognosis (Sheu et al, 1999).
However, we did not find the ratio between CD4þ and CD8þ
cells to be correlated with prognosis.
CD8 is also a glycoprotein serving as a co-receptor for the T-cell
receptor. It is expressed on cytotoxic T cells that have the
capability of killing tumour cells. In a recent study by Piersma et al
(2007) the presence of intratumoural CD8þ cells in cervical
cancer correlated with the lack of pelvic lymph node spread and
therefore correlated indirectly with prognosis. Also in other cancer
types as ovarian cancer (Sato et al, 2005), endometrial cancer
(Kondratiev et al, 2004), colon cancer (Guidoboni et al, 2001) and
lung cancer (Eerola et al, 2000) have intratumoural CD8þ cells
that have been correlated to improved prognosis.
The immune response towards cancer is very complex and the
different cell types interact and influence each other (Eiben et al,
2002). In our study we found CD3þ cells to be the strongest
predictor of prognosis and the reason might be that the presence of
several immune cell subtypes and not one in particular is
Table 3 Cox’s proportional hazards model (univariate) of relapse of disease
Crude model Adjusted model
Crude HR 95% CI P-value Adjusted HR 95% CI P-value
CD3 intratumoral 294/118 0.48 [0.27–0.86] 0.01 0.49 [0.28–0.86] 0.01
CD3 peritumoral 795/2043 0.27 [0.13–0.58] 0.0008 0.29 [0.14–0.61] 0.001
CD4 intratumoral 16/213 0.55 [0.31–1.00] 0.05 0.55 [0.31–1.00] 0.05
CD4 peritumoral 106/463 0.62 [0.39–0.99] 0.04 0.61 [0.38–0.98] 0.04
CD8 intratumoral 198/852 0.41 [0.21–0.81] 0.01 0.41 [0.21–0.80] 0.009
CD8 peritumoral 448/1234 0.38 [0.20–0.74] 0.004 0.37 [0.19–0.73] 0.004
HR¼hazard ratio. Cox’s proportional hazards regression modeling was performed to determine the association between density of immune cells and relapse of disease. In the























































Figure 1 Relapse-free survival in stage IB-IIA shown for each quartile of
density of peritumoural CD3þ cells.
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simportant. The cytotoxic T cells are very important in cancer
defence but their effect is dependent on the presence of other cells,
including T helper cells. We found both intra- and peritumoural
cell densities to be associated with prognosis and as opposed to
other studies (Bethwaite et al, 1996; Chao et al, 1999) the densities
of peritumoural CD3þ and CD8þ cells were stronger predictors
than intratumoural cells.
According to our study, analyses of the in situ cellular immune
response at the time of diagnosis can divide patients into groups,
having different risks of relapse even after therapy. A relative
simple evaluation of the density of peritumoural CD3þ cells is a
possibly useful predictive marker of relapse, and the group of
patients having the lowest density of cells should be controlled
extra carefully for relapse of disease.
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